Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Filings indexed 443 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 85% confidence The document is a Korean ‘분기보고서’ (quarterly report) for the period Jan 1 to Mar 31, 2026, containing detailed financial statements, business overview, segment results, risk management notes, etc. This is a full interim/quarterly report, not merely an announcement or summary. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a detailed "주식등의 대량보유상황보고서" (Large Shareholding Status Report) filed under Korea’s Capital Market and Financial Investment Business Act. It reports the number of shares and voting rights held by the reporting party and its related entities, updates on threshold crossings, and explanations of ownership changes. This matches the definition of a Major Shareholding Notification (crossing significant ownership thresholds).
2026-04-21 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 85% confidence The document is a formal corporate disclosure detailing the acquisition of the company’s own convertible bonds (debt instruments) prior to maturity under a put option exercise. This describes a financing activity and a capital structure change (debt issuance and repurchase), fitting the definition of a Capital/Financing Update (CAP). It is not a share repurchase (POS), not a regulatory filing notice for a report (RPA/RNS), nor any other category like dividends, AGM materials, or M&A.
2026-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the results of a company’s regular (annual) shareholders’ meeting (‘정기주주총회결과’). It details each agenda item (financial statements approval, dividend resolution, board appointments, charter amendments, share plans, etc.) along with voting outcomes and percentages. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which is used for official vote results from an AGM or EGM.
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 94% confidence The document is a formal notification filed to the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, dismissal, or mid-term resignation of outside (independent) directors. It details names, dates of appointment or resignation, terms and background, which clearly pertains to changes in the company’s board of directors. Therefore, it falls under the Board/Management Information category.
2026-03-27 Korean
본점소재지변경
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory disclosure by HLB테라퓨틱스 announcing a change of its registered head office address. It provides details of the old and new addresses, effective date, and board resolution date. This is a routine corporate announcement that does not fit into specific categories like earnings release, share issue, management change, or dividend notice. Therefore it falls into the fallback category of general regulatory filings.
2026-03-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.